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Abstract 31 
Gonadotropin inhibitory hormone (GnIH, human homologue of RFRP-3) suppresses 32 
gonadotropin secretion in animal models, but its effects have not been studied in the human. 33 
Objective  34 
We tested the hypotheses that exogenous GnIH inhibits LH secretion a) in postmenopausal 35 
women, and b) in men concurrently administered exogenous kisspeptin.  36 
Design 37 
Following in vitro and in vivo pre-clinical studies to functionally characterize the GnIH 38 
peptide, a dose-finding study (human GnIH 1.5 to 150 µg/kg/h, iv for 3h) was undertaken, 39 
and 50 µg/kg/h selected for further evaluation.  40 
Five postmenopausal women were administered 50 µg/kg/h iv infusion for 3h or vehicle on 41 
two separate days.   42 
Four men were administered kisspeptin-10 (0.3 µg/kg iv bolus) with simultaneous infusion of 43 
GnIH (50 µg/kg/h, iv for 3h) or vehicle. 44 
Participants. 45 
Healthy postmenopausal women (mean age 58±2 years, LH: 30.8±2.9 IU/L, FSH: 78.7±6.4 46 
IU/L, estradiol: <50 pmol/L) and men (39.8±2.1 years, mean total testosterone 12.1±1.8 47 
nmol/L, LH 2.2±0.2 IU/L).  48 
Primary Outcome 49 
Change in area-under-curve of LH during GnIH vs. vehicle.  50 
Results 51 
During GnIH administration in postmenopausal women, LH secretion decreased (∆ AUC -52 
9.9±1.8 IU/3h) vs. vehicle (∆ AUC -0.5±1.7 IU/3h) (P= 0.02). Kisspeptin-10 stimulated LH 53 
responses in men was not affected by GnIH co-administration (60-min AUC of LH 6.2±0.8 54 
IU/h with kisspeptin-10 alone, 6.3±1.0 IU/h, kisspeptin-10 with GnIH, P = 0.72).  55 
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Exogenous GnIH was well tolerated, with no adverse events reported. 56 
Conclusions.  57 
GnIH decreased LH secretion in postmenopausal women in this first-in-human study. 58 
Kisspeptin-stimulated LH secretion in men was not inhibited during concomitant 59 
administration of GnIH. 60 
  61 
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Introduction 62 
Pulsatile secretion of gonadotropin releasing hormone (GnRH) stimulates the secretion of 63 
gonadotropins (LH and FSH) and the downstream secretion of gonadal steroid hormones.1-3 64 
Gonadotropin inhibitory hormone (GnIH) is a hypothalamic neuropeptide initially discovered 65 
in birds as an inhibitor of LH secretion
4
 but its activity has not been studied in  humans. We 66 
report the first human studies on the effect of exogenous GnIH on LH secretion. 67 
The avian GnIH peptide (SIKPSAYLPLRF-NH2) has one human homologue which is 68 
inactive and, two orthologues which have the characteristic carboxyl terminal RF-amide. 69 
RFRP-1 (MPHSFANLPLRF-NH2) and RFRP-3 (VPNLPQRF-NH2,), were isolated and 70 
structurally identified in the human hypothalamus.
5
 GnIH inhibits GnRH-stimulated 71 
mobilization of intracellular calcium in avian
4
, ovine
6
 and bovine
7
 gonadotropes in vitro – 72 
suggesting a pituitary locus of action. These data, and other evidence from a range of species5, 73 
8-14
, reviewed recently elsewhere
15
, indicate that GnIH is a specific inhibitor of gonadotropin 74 
secretion in mammals, signaling through the GnIH receptor (GnIH-R, GPR147) via inhibition 75 
of cyclic AMP production. GnIH neurons display close apposition to GnRH neurons in 76 
sheep
16
 , non-human primate
17
 and in human
5
 hypothalami, suggesting that GnIH may also 77 
directly regulate GnRH secretion.  78 
Following pre-clinical studies to characterize the activity of the GnIH peptide in vitro and in 79 
the ovariectomized ewe, we investigated the effect of GnIH on LH secretion in two human 80 
models of increased GnRH secretion: in postmenopausal women, and in in healthy men 81 
administered exogenous kisspeptin.   82 
Methods 83 
GMP kisspeptin and GnIH 84 
Kisspeptin-10 and GnIH peptides were custom synthesized to GMP standards (Bachem 85 
GmBH, Weil am Rhein, Germany). Purity was assessed by HPLC at 97% with a mass 86 
balance of 98.8%. Both peptides were made up within the hour before injection/infusion by 87 
diluting 1 mg of lyophilized peptide in 5 ml sterile normal saline. The bolus dose of 88 
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kisspeptin-10 (0.3 µg/kg) was selected for acute LH stimulation tests based on our previous 89 
dose-finding study of kisspeptin-10 18 and other published data.3 90 
Characterisation of GnIH in vitro 91 
The objective of these in vitro studies was to compare the biological activity of the custom-92 
synthesised GnIH peptide used in the present study with that of GnIH previously used in 93 
published data involving non-human species. Whole-cell receptor binding and CRE-luciferase 94 
assays were carried out in parallel using the custom-synthesized GMP GnIH and a custom 95 
synthesized preparation (EzBiolab, Carmel, IN, USA) used extensively by our laboratory. 96 
Whole-cell receptor binding assay  97 
The methods are described in detail elsewhere
19
 but in brief, COS-7 cells were electroporated 98 
with 10 µg NPFFR1 (GPR147) and seeded in 12 well plates. Forty eight hours post 99 
transfection cells were incubated in HEPES-DMEM with 100000 cpm 125I radiolabelled-100 
RFRP3/well and increasing concentrations of non-radiolabelled peptide in the range of 0-101 
1µM for 4 hours at 4°C. Cells were then rapidly washed twice with cold PBS 102 
(+MgCl2/CaCl2). Thereafter, 0.5mL 0.1M NaOH was added to the cells and incubated at 103 
room temperature for 15 minutes to lyse the cells. Cell lysates were transferred to plastic 104 
tubes and bound radioactivity counted with a Berthold LB2111 gamma counter for 1 minute. 105 
CRE-Luciferase Assay  106 
HEK 293T cells were seeded in 24 well plates coated with Matrigel (BD Biosciences). The 107 
next day, cells were chemically transfected (X-tremeGENE HP DNA Transfection Reagent 108 
(Roche)) with GPR147 and CRE-Luc reporter gene plasmid DNA in a 1:1 DNA ratio.  Plates 109 
were incubated for 24 hours post transfection and then washed twice with phosphate buffered 110 
saline (PBS+). Thereafter, starving media (DMEM [Dulbecco’s modified Eagle's medium], 111 
1% pen/strep, 4mM L-glutamine, 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 112 
HEPES) was added to the cells overnight. Media was aspirated and replaced 0.5mL of 113 
compound dilutions prepared in starving media. Plates were incubated for 6 hours at 37 °C 114 
after which they were transferred to ice and washed with cold PBS+. Diluted passive lysis 115 
buffer (20 µL) was added to each well and plates placed on a shaker at 1050 rpm for 15 116 
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minutes at room temperature. Lysates were diluted 1:4 and 20 µL was transferred to a white, 117 
flat bottomed 96 well plate. Luciferase activity was measured for 10 seconds on a Lumat 118 
LB9501 Luminometer after 100 µL LARII was added to each well. 119 
LH inhibition by GnIH in ewes 120 
Animals and peptide infusion regime 121 
Groups of 4 ovariectomised ewes were held in single pens and both jugular veins were 122 
cannulated on the day prior to experimentation to allow blood sampling and infusion. Venous 123 
blood samples were taken at 10 min intervals for 7.5 hours, in 2.5 hour blocks, before, during 124 
and after infusion of either GnIH or vehicle (saline). The animals received a loading dose of 125 
1mg and then an infusion of 1 mg/h, using an infusion rate of 1ml/h. All ovine experiments 126 
were carried out at the University of Monash (IJC) in compliance with regulations and ethical 127 
standards. 128 
Radioimmunoassay of ovine LH 129 
LH in plasma was measured as previously described20 using NIH-oLH-S18 as the standard 130 
and NIDDK-anti-oLH-I as the antiserum. Iodinated ovine LH (125 I-NIDDK-AFD-9598B) 131 
was used as tracer. Assay sensitivity was 0.1 ng/ml. Intra-assay coefficient of variation (CV) 132 
was <10% between 0.6 and 13.7 ng/ml and inter-assay CV was 7.8% at 10.4 ng/ml and 9.5% 133 
at 20.3 ng/ml.21  134 
LH Pulse analysis in ovine studies 135 
An LH pulse was defined as having occurred when the assay value of a given sample 136 
exceeded the assay value of the previous sample by at least 3 standard deviations, as well as 137 
other criteria detailed previously22, using error estimates generated by the computer program 138 
of Salamonsen et al.23 Comparisons of LH pulse amplitude, inter-pulse interval, and mean LH 139 
between groups infused with GnIH and vehicle were made using two-way ANOVA. 140 
 141 
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Human studies 142 
Participants 143 
Five healthy postmenopausal women (mean age 58±2 yrs, 12.4±2.6 yrs since last menstrual 144 
period, LH: 30.8±2.9 IU/L, FSH: 78.7±6.4 IU/L, estradiol: <50 pmol/L) and four healthy 145 
adult men (mean age 39.8±2.1 yrs, total testosterone 12.1±1.8 nmol/L, LH 2.2±0.2 IU/L and 146 
FSH 4.8±12 IU/L took part in the study. LH, FSH and testosterone were all within normal 147 
range in the men, and this was confirmed on at least one additional morning sample). 148 
Baseline physical examination, full blood count, renal function, liver function, and serum 149 
electrolytes were within normal limits. All volunteers provided written informed consent to 150 
take part in this study, which was approved by the South East Scotland Research Ethics 151 
Committee (10/S1101/53). The study was also approved by the Edinburgh Clinical Research 152 
Facility Phase 1 and First-in-Human Study Review Committee (Ref E10903).  153 
Peptide infusion protocols for human studies 154 
First, we set to establish a safe and eff ctive dose that achieved nanomolar concentrations of 155 
RFRP3 in the peripheral circulation when administered as an intravenous infusion in two 156 
post-menopausal women (dose finding study). Second, the effects of the maximally effective 157 
dose (identified from the dose-finding study as approximately 50 µg/kg/h) was studied in 3 158 
additional post-menopausal women, to give a total n=5 for this dose. Third, four healthy men 159 
were given intravenous boluses of kisspeptin in the presence or absence of GnIH 50 µg/kg/h 160 
administered concurrently as intravenous infusion (Kisspeptin-GnIH Study). 161 
Effects of GnIH on LH in post-menopausal women 162 
a) Dose-finding study 163 
The median inhibitory concentration of GnIH at its cognate receptor (GPR147) is 1-2 nM24. 164 
The objective of this study was therefore to identify a dose at which circulating GnIH 165 
concentrations greater than 1 nM were achieved.  166 
Two healthy post-menopausal women were admitted six times to our clinical research 167 
facility, with a minimum inter-visit interval of a week. Each of these visits involved six hours 168 
of frequent (every 10-min) venous blood sampling to assess effects on LH secretion. After 169 
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three hours of baseline sampling, an infusion of GnIH (1.5, 5, 15, 50 and 150 µg/kg/h) or 170 
vehicle (normal saline) was administered for a further three hours. At the start of this 171 
infusion, an intravenous bolus of GnIH (25% of hourly infusion dose) or vehicle was 172 
administered, simulating the studies in which GnIH was effective in ovariectomised ewes. For 173 
safety reasons, doses were administered in increasing order in an unblinded manner under 174 
medical supervision and participants were observed in the research facility for at least an hour 175 
after the infusion completed. LH sampling was opportunistically continued at 10-min interval 176 
during this additional hour of safety monitoring. 177 
 In addition to collection of serum for hormone assays, plasma samples were collected 178 
immediately before as well as at regular intervals up to four hours (at 30, 60, 120, 150, 179, 179 
190, 200, 210, 220, 230 and 240 minutes) after commencing the infusion for pharmacokinetic 180 
assessment to quantify circulating GnIH. GnIH concentrations were estimated using liquid 181 
chromatography tandem mass spectrometry. A DPP-IV inhibitor (Diprotin A, 0.1mM final 182 
concentration; Sigma I9759) and protease inhibitor cocktail (Sigma P8340, 1x final 183 
concentration; both sourced from Sigma-Aldrich, St. Louis, MO, USA) were added to these 184 
samples to inhibit breakdown of GnIH after serum collection. 185 
Blood pressure, pulse rate, and peripheral oxygen saturations were measured with standard 186 
automated techniques. Full blood count, serum electrolytes, liver and renal function were 187 
checked at the beginning and end of each visit. 188 
b) Effects of 50 µg/kg/h intravenous GnIH in post-menopausal women 189 
In addition to the two women who participated in dose-finding study, three more healthy 190 
postmenopausal women received 50 µg/kg/h intravenous infusions of GnIH (with a 12.5 191 
µg/kg intravenous bolus at the start of the infusion) and vehicle for three hours each on two 192 
separate days, at least a week apart, using the LH sampling protocol outlined above.  193 
LH pulsatility in all five women during the 50 µg/kg/h of GnIH was compared with the 194 
pulsatility observed during the infusion of vehicle. 195 
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Effects of GnIH on kisspeptn-10 stimulation of LH in healthy men 196 
The objective of this study was to test the hypothesis that co-administration of GnIH would 197 
attenuate the stimulatory LH response elicited by kisspeptin. 198 
Healthy male volunteers (n=4) were admitted twice to our clinical research facility for 7.5 199 
hours and LH samples obtained at 10-minute intervals. Two intravenous boluses of 200 
kisspeptin-10 (0.3 µg/kg, 23 pmol/kg) were administered at 60-minutes and 270 minutes. On 201 
the first visit, an intravenous infusion of saline was started at 240 minutes. On the second 202 
visit, a 50 µg/kg/h intravenous infusion of GnIH was commenced at the identical time-point 203 
(240 minutes) to that of vehicle infusion, along with a 12.5 µg/kg intravenous bolus of GnIH 204 
administered at the start of this infusion which continued for 180 minutes. This protocol is 205 
identical to the 50 µg/kg/h infusion protocol used in the dose-finding and replication studies 206 
described above. 207 
Human LH pulsatility analysis and statistical comparisons 208 
Blood samples were centrifuged immediately at 4 C for 10 min at 3000 rpm and serum frozen 209 
at -20 C until analysis. LH was determined by ELISA as previously described18.  Inter-assay 210 
coefficient of variation for all hormonal assays was less than 5% at the concentrations 211 
measured. Intra-assay coefficient of variation of LH was 2.9%. All samples from each of the 212 
study visits were analyzed together. 213 
Area-under-curve (AUC) of LH was calculated using trapezoid integration. In studies to 214 
assess the impact of exogenous GnIH on LH secretion, 180-min AUC before and during the 215 
infusion of GnIH were calculated to derive ∆AUC LH - the arithmetic difference of AUC 216 
over three hours before and during the infusion. Paired Student’s t tests used to compare 217 
∆AUC LH during vehicle and GnIH infusions. 218 
In the kisspeptin-GnIH study, 60-min AUC was calculated during three periods: Baseline 219 
(first hour of the study) and 60-min after each of the kisspeptin-10 boluses. Repeated 220 
measures ANOVA was used to assess variance in 60-min AUC and multiple comparisons 221 
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made using Fishers Least Significant Difference (LSD) test. We have previously shown the 222 
sensitivity of this approach to detect LH response to kisspeptin-10 18, 25, 26.  223 
LH pulses were identified and mass-per-pulse (MPP) and basal LH secretion calculated using 224 
a deconvolution algorithm using cluster analysis with 93% sensitivity and specificity on 225 
blinded data27. Paired Student’s t test was used to assess changes in pulse frequency, mass-226 
per-pulse and basal LH secretion. 227 
Data are presented as mean±SEM. A two-sided P<0.05 was regarded as statistically 228 
significant for all analyses. The statistical software package Graphpad Prism 6 for Mac OSX 229 
(Graphpad, La Jolla, CA 92037 USA) was used. 230 
Results 231 
In vitro studies 232 
GMP custom-synthesised GnIH (Bachem) and comparator peptide (EZbiolab) induced an 233 
inhibition of forskolin-induced accumulation of cAMP with similar potencies (Supplementary 234 
Fig 1).  Both peptides also displayed high affinity for the receptor with no statistically 235 
significant difference in the IC50 (data not shown). 236 
In summary, the GnIH peptide used in the present human study thus has identical binding and 237 
signalling characterstics to a peptide preparation previously used in non-human studies at the 238 
GPR147 receptor.  239 
LH Inhibition by GnIH in Ewes 240 
Infusion of GnIH significantly reduced the amplitude of LH pulses in ovariectomised ewes 241 
(Supplementary Fig 2). LH pulse amplitude decreased from 0.9±0.1 ng/ml before the GnIH 242 
infusion to 0.4±0 ng/ml during it (P <0.002) and returned to baseline (0.7±0.1 ng/ml) 243 
following discontinuation. In the control vehicle infusion group, LH pulse amplitude 244 
remained unchanged at 1±0.1 ng/ml before, 1.3±0.2 ng/ml during and 1.3±0.3 ng/ml after 245 
infusion.  246 
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There were no significant changes in LH pulse frequency or mean LH during either GnIH or 247 
vehicle infusions. GnIH infused sheep had 3.8±0.25 pulses before, and 4.0±0 pulses during 248 
the infusion, and 4.0±0.4 pulses in the post-infusion study period. Control animals infused 249 
with vehicle were observed to have 3.5±0.5, 3.75±0.25 and 3.75±0.5 pulses during 250 
corresponding sampling windows.  251 
Individual animal-level data on LH secretion in both GnIH and vehicle treated groups are 252 
tabulated in supplementary table 1. 253 
Effects of GnIH on LH in postmenopausal women 254 
Dose finding study 255 
All doses of GnIH were well tolerated, with no adverse events. Both women showed modest 256 
but dose-dependant suppression of LH secretion during GnIH infusion. One subject achieved 257 
maximal reduction in AUC of LH at 15 µg/kg/h dose (∆ AUC -9.7 IU/L/3h) and the other at 258 
50 µg/kg/h (∆ AUC -10.9 IU/L/3h) (Fig 1A). 259 
During infusion of 50 µg/kg/h, circulating concentrations of GnIH rose from below the limits 260 
of quantification (1ng/mL) before administration to 2.4 ±0.4 ng/ml during the infusion (range 261 
1.2-3.8 ng/ml; 1.2-3.9 nM) and 6.5±1.8 ng/ml (range 1.9-11.9 ng/ml; 2-12.3 nM) in the two 262 
women. GnIH became undetectable 10 minutes after the end of the infusion. 263 
The highest dose studied (150 µg/kg/h) resulted in higher plasma concentrations of GnIH 264 
(10.1±1.5 ng/mL; 10.4±1.5 nM) and (11.1±2.5 ng/mL; 11.5±2.6 nM) in the two subjects. 265 
However, this increase in circulating peptide concentration was not associated with larger 266 
reductions in LH secretion than that observed with the 50 µg/kg/h dose.  Therefore, the lowest 267 
dose that achieved nanomolar concentrations in peripheral circulation, i.e. 50 µg/kg/h, was 268 
selected for further studies. 269 
LH inhibition by GnIH in post-menopausal women 270 
GnIH infusion (50 µg/kg/h) significantly decreased LH secretion (∆ AUC -9.9±1.8 IU/3h) 271 
when compared to the infusion of vehicle (∆ AUC -0.5±1.7 IU/3h) in the five women (p= 272 
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0.02, Fig 1B). Decreases in mean LH was observed in four out of the five women studied. 273 
Individual volunteer-level data on mean LH secretion before, during and after saline and 274 
GnIH treatments are tabulated in supplementary table 2. 275 
There was no effect on pulsatile LH secretion (figure 2). Baseline pulse frequency of 0.8±0.1 276 
pulse/h remained unchanged during GnIH treatment, at 0.8±0.1 pulse/h. Nevertheless, mass-277 
per-pulse showed a numerical increase, from 20.2±4.5 IU/l at baseline to 27.8±6.4 IU/l during 278 
GnIH infusion (P = 0.052). Consistent with these, the total pulsatile secretion of LH also 279 
showed a numerical increase without statistical significance - at 100.6±26.6 IU/L/3h at 280 
baseline to 139.1±38.2 IU/L/3h (P = 0.124) during GnIH infusion.  281 
Co-administration of GnIH and kisspeptin-10 in men 282 
Kisspeptin-10 bolus (0.3 µg/kg iv) significantly increased LH secretion, with 60-min AUC of 283 
LH increasing from 2.8±0.8 IU/L/h to 6.5±0.9 after each of the two boluses in the control 284 
visit. (ANOVA P = 0.005, Fisher’s LSD P = 0.003, baseline vs. kisspeptin boluses; 0.96 285 
(comparing the two kisspeptin boluses), Fig 3A. 286 
During concurrent administration of GnIH, both boluses of kisspeptin-10 also elicited 287 
significant increases in LH secretion, with 60-min AUC of LH increasing from 3.1±0.5 288 
IU/L/h to 6.2±0.8 IU/L/h with kisspeptin-10 alone vs. 6.3±1.0 IU/L/h with kisspeptin-10 in 289 
the presence of GnIH respectively (Fisher’s LSD P <0.005). There was no statistical 290 
difference between responses to the two kisspeptin-10 boluses administered before or during 291 
GnIH infusion (Fisher’s LSD P = 0.715), Fig 3B. Individual volunteer-level 60-min AUC 292 
during baseline and after the two kisspeptin-10 boluses are tabulated in supplementary table 293 
3. Figure 4 provides exemplar LH profiles from a participant during GnIH and vehicle 294 
infusion visits. 295 
Safety of GnIH 296 
GnIH infusions were well tolerated with no serious adverse events reported. Heart rate and 297 
blood pressure, which were monitored intensely during study visits, showed no significant 298 
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change.  Serum electrolytes, renal function, full blood count and liver function monitored at 299 
all study visits also remained unchanged. 300 
Discussion 301 
The present study provides first-in-human data on the effects of exogenous GnIH effects on 302 
LH secretion in women and men, in paradigms of increased GnRH secretion. In 303 
postmenopausal women, GnIH administration resulted in a modest suppression of LH 304 
secretion, while it did not affect kisspeptin-stimulated LH secretion in men. GnIH was well 305 
tolerated by men and women who took part in this first in man study, providing reassurance 306 
about its safety for future clinical studies. 307 
Infusions of GnIH (up to the dose of 150 µg/kg/h in two post-menopausal women, 50 µg/kg/h 308 
in all other men and women) for three hours were well tolerated. Serum concentrations in the 309 
low nanomolar range were achieved with continuous intravenous infusion of GnIH at 50 310 
µg/kg/h and associated with significant decrease in LH secretion (AUC of LH) in post-311 
menopausal women. We demonstrated that the circulating concentrations of 1.2-12.3 nM/L 312 
achieved are sufficient to bind to the GPR147 receptor and inhibit forskolin-stimulated cAMP 313 
generation (Fig 1). 314 
Our results are consistent with decreased LH secretion observed in large animal models (ewes 315 
and calves) exposed to GnIH.6, 7 In rodents, the effects of GnIH appear to show sexual 316 
dimorphism. Male rats
9, 14
 and hamsters
8
 respond with gonadotropin suppression, while 317 
female rats showed no change in LH or FSH when the peptide was administered 318 
intracerebroventricularly. 28  319 
The pattern of reduction in LH secretion observed in post menopausal women in our study 320 
during GnIH administration appears to be broadly concordant with that observed in 321 
previously published ovine
6
 and bovine models
7
. Post-menopausal women in the present 322 
study showed no change in LH pulse frequency; the corresponding ovine model 323 
(ovariectomised sheep) also showed no reduction in pulse frequency in the present study as 324 
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well as in previous studies.6 A previous study using a bovine model did show a reduction in 325 
pulse frequency7 but  in that study GnIH was administered as multiple boluses rather than by 326 
infusion. Furthermore, the bovine models used were castrated males, which does not allow 327 
direct comparison with the data in the present study.  328 
The magnitude of reduction of LH in human volunteers in the present study appears to be 329 
lower than the marked reduction in serum LH observed in ovariectomised sheep.
6
 There is 330 
considerable inter-species difference in the effects of GnIH29, which may explain some of the 331 
differences.  Therefore, the most parsimonious explanation for the differential responses in 332 
ovine models and human volunteers is potential inter-species variability. Furthermore, as our 333 
study was based only on a small number of participants, the true effect size of LH response to 334 
GnIH in a wider population cannot be reliably extrapolated. In addition, administration of 335 
exogenous peptide hormones, i.e., the experimental paradigm employed here, is not an 336 
appropriate technique to study the physiological role of the peptide. However, even when 337 
taking study limitations into consideration, the limited suppression of LH observed in the 338 
present study suggests that pharmacological application of GnIH (or its agonists) in human 339 
disorders of excess LH secretion may not be feasible.  340 
GnIH had no effect on kisspeptin-stimulated LH secretion in men in the present study where 341 
50 µg/kg/h was administered as continuous intravenous infusion. In addition to its main 342 
objectives, the present study also assessed the effects of repeated doses of kisspeptin-10 343 
boluses within the same individual – four boluses on two separate study days. These data 344 
showed that there was remarkable intra-individual consistency in LH response to kisspeptin-345 
10 (supplemental table 3). This is distinct from the tachyphylaxis observed on repeated dosing 346 
of kisspeptin-54
3
 or with longer-acting kisspeptin analogues.
30
 This finding could lend 347 
support for the continuing development of kisspeptin-10 as a physiologic probe to ascertain 348 
GnRH function in or as a potential therapeutic option to stimulate GnRH endogenously.3  349 
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We chose kisspeptin-10 administration as a model of LH stimulation to study the effects of 350 
GnIH on LH secretion in men. Kisspeptin acts via endogenous GnRH secretion and results in 351 
a doubling in peripheral LH concentrations, comparable to an endogenous LH pulse, and is 352 
thus a more physiologically relevant stimulus than exogenous GnRH, which elicits around a 353 
10-fold rise in LH.3 Furthermore, we have previously shown that the acute LH-response to 354 
kisspeptin in men is not affected by prevailing sex-steroid status.
25
 LH response to kisspeptin 355 
remained unchanged with concurrent administration of GnIH. 356 
 With the limited LH suppression observed in these first-in-man studies in both men and 357 
women, it is reasonable to speculate that the role of GnIH in the regulation of LH secretion in 358 
the human may be less robust than in other species. Nevertheless  these studies have 359 
limitations. As a first-in-human study with associated safety considerations, the exposure to 360 
human volunteers in the study was limited to 3 hours and only a small number of volunteers 361 
were studied. Furthermore, we did not undertake a separate dose-finding study in men, but 362 
have assumed similar pharmacokinetics in men and women.  363 
GnRH-induced gonadotropin subunit gene transcription is suppressed by GnIH orthologues 364 
by inhibiting adenylate cyclase/cAMP/protein kinase A-dependent ERK activation.31 This 365 
transcriptional effect suggests that a longer exposure paradigm may have achieved greater 366 
suppression of LH secretion. However, the rapid clearance of GnIH from circulation observed 367 
here makes it challenging to deliver sufficient quantities of the native peptide intravenously to 368 
maintain stable serum concentrations over long durations. This challenge has been effectively 369 
overcome for GnRH and other small peptide hormones by incorporation of D-amino acids to 370 
reduce proteolytic degradation and by formulating in biodegradable polymers which can 371 
deliver efficacious levels of peptide for up to one year. Therapeutic potential of GnIH to treat 372 
disorders characterised by increased LH secretion (e.g. PCOS, menopausal hot flushes, 373 
precocious puberty) needs to be assessed in context of emerging data on kisspeptin and 374 
neurokinin B modulation. Prima facie, GnIH appears to be a less potent tool in comparison to 375 
these approaches.3, 32 376 
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In conclusion, in this first-in-human study, we have demonstrated that exogenously 377 
administered GnIH has a suppressive effect on LH secretion in postmenopausal women and 378 
that kisspeptin-10 mediated LH secretion in men is unaffected during concomitant 379 
administration of GnIH. Further studies, are required to fully elucidate the physiological 380 
mechanisms and the therapeutic potential for GnIH.  381 
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 389 
Figure 1: Reductions in 180-minute Area-under-curve (∆AUC) of Luteinising Hormone in 390 
postmenopausal women administered GnIH. A, ∆AUC of LH in two postmenopausal women 391 
administered vehicle and GnIH infusions at 1.5, 5, 15, 50 and 150 µg/kg/h. Each of the data 392 
series represents data from an individual volunteer. Each series represents a single woman 393 
receiving all five doses and vehicle. One subject only had 0.07 unit decrease. B, ∆AUC  of 394 
LH in five postmenopausal women administered vehicle (white column) and RFPR-3 395 
infusion at 50 µg/kg/h (black column). The data include those of the 50 µg/kg/h from the two 396 
women receiving the various doses (1A above) and four additional women (* P=0.02) 397 
1A        398 
 399 
 400 
1B 401 
 402 
  403 
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Figure 2: LH pulse profiles of five postmenopausal women administered 50 mcg/kg/hour 404 
GnIH (red squares) and saline infusions (blue triangles). Blood samples were drawn at 10-min 405 
intervals throughout the study. Intravenous infusion of GnIH was maintained for three hours, 406 
from 0 to 180 min, and an intravenous bolus of GnIH (12.5 µg/kg) was administered at time 407 
0. 408 
 409 
  410 
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Figure 3. LH secretion (60 minute AUC, IU/h) at baseline and during the hour after healthy 411 
men were administered boluses of kisspeptin-10 (0.3 µg/kg). Co-administration of vehicle (A) 412 
or GnIH (B) did not impact on the stimulatory effect of kisspeptin on LH secretion. * p <0.05. 413 
 414 
 415 
  416 
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 417 
Figure 4: LH pulse profiles of one of the male volunteers on the two days when  vehicle 418 
(squares) and GnIH (circles) were administered for three hours - from 0 min to 180 min. 419 
Patients had one hour of LH profiling at the beginning of each session to quantify baseline 420 
LH secretion (-240 to  -180 min). Kisspeptin was administered at -180 and +30 mins during 421 
both these study visits, to quantify 60-min area-under-curve of LH following each of these. 422 
  423 
Page 21 of 32 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 22
 424 
References 425 
1 Millar, R.P. (2005) GnRHs and GnRH receptors. Animal Reproduction Science 88, 5-426 
28. 427 
2 Balasubramanian, R., Dwyer, A., Seminara, S.B., Pitteloud, N., Kaiser, U.B. & Crowley, 428 
J.W.F. (2010) Human GnRH Deficiency: A Unique Disease Model to Unravel the Ontogeny of 429 
GnRH Neurons. Neuroendocrinology, 81-99. 430 
3 Skorupskaite, K., George, J.T. & Anderson, R.A. (2014) The kisspeptin-GnRH pathway 431 
in human reproductive health and disease. Human Reproduction Update 20, 485-500. 432 
4 Tsutsui, K., Saigoh, E., Ukena, K., Teranishi, H., Fujisawa, Y., Kikuchi, M., Ishii, S. & 433 
Sharp, P.J. (2000) A Novel Avian Hypothalamic Peptide Inhibiting Gonadotropin Release. 434 
Biochemical and Biophysical Research Communications 275, 661-667. 435 
5 Ubuka, T., Morgan, K., Pawson, A.J., Osugi, T., Chowdhury, V.S., Minakata, H., 436 
Tsutsui, K., Millar, R.P. & Bentley, G.E. (2009) Identification of Human GnIH Homologs, RFRP-437 
1 and RFRP-3, and the Cognate Receptor, GPR147 in the Human Hypothalamic Pituitary Axis. 438 
PLoS ONE 4, e8400. 439 
6 Clarke, I.J., Sari, I.P., Qi, Y., Smith, J.T., Parkington, H.C., Ubuka, T., Iqbal, J., Li, Q., 440 
Tilbrook, A., Morgan, K., Pawson, A.J., Tsutsui, K., Millar, R.P. & Bentley, G.E. (2008) Potent 441 
Action of RFamide-Related Peptide-3 on Pituitary Gonadotropes Indicative of a 442 
Hypophysiotropic Role in the Negative Regulation of Gonadotropin Secretion. Endocrinology 443 
149, 5811-5821. 444 
7 Kadokawa, H., Shibata, M., Tanaka, Y., Kojima, T., Matsumoto, K., Oshima, K. & 445 
Yamamoto, N. (2009) Bovine C-terminal octapeptide of RFamide-related peptide-3 446 
suppresses luteinizing hormone (LH) secretion from the pituitary as well as pulsatile LH 447 
secretion in bovines. Domestic Animal Endocrinology 36, 219-224. 448 
8 Kriegsfeld, L.J., Mei, D.F., Bentley, G.E., Ubuka, T., Mason, A.O., Inoue, K., Ukena, K., 449 
Tsutsui, K. & Silver, R. (2006) Identification and characterization of a gonadotropin-inhibitory 450 
system in the brains of mammals. Proceedings of the National Academy of Sciences of the 451 
United States of America 103, 2410-2415. 452 
9 Johnson, M.A., Tsutsui, K. & Fraley, G.S. (2007) Rat RFamide-related peptide-3 453 
stimulates GH secretion, inhibits LH secretion, and has variable effects on sex behavior in the 454 
adult male rat. Hormones and Behavior 51, 171-180. 455 
10 Gibson, E.M., Humber, S.A., Jain, S., Williams, W.P., Zhao, S., Bentley, G.E., Tsutsui, K. 456 
& Kriegsfeld, L.J. (2008) Alterations in RFamide-Related Peptide Expression Are Coordinated 457 
with the Preovulatory Luteinizing Hormone Surge. Endocrinology 149, 4958-4969. 458 
11 Murakami, M., Matsuzaki, T., Iwasa, T., Yasui, T., Irahara, M., Osugi, T. & Tsutsui, K. 459 
(2008) Hypophysiotropic role of RFamide-related peptide-3 in the inhibition of LH secretion 460 
in female rats. Journal of Endocrinology 199, 105-112. 461 
12 Sari, I.P., Rao, A., Smith, J.T., Tilbrook, A.J. & Clarke, I.J. (2009) Effect of RF-Amide-462 
Related Peptide-3 on Luteinizing Hormone and Follicle-Stimulating Hormone Synthesis and 463 
Secretion in Ovine Pituitary Gonadotropes. Endocrinology 150, 5549-5556. 464 
13 Ubuka, T., Inoue, K., Fukuda, Y., Mizuno, T., Ukena, K., Kriegsfeld, L.J. & Tsutsui, K. 465 
(2012) Identification, Expression, and Physiological Functions of Siberian Hamster 466 
Gonadotropin-Inhibitory Hormone. Endocrinology 153, 373-385. 467 
14 Pineda, R., Garcia-Galiano, D., Sanchez-Garrido, M.A., Romero, M., Ruiz-Pino, F., 468 
Aguilar, E., Dijcks, F.A., Blomenr√∂hr, M., Pinilla, L., van Noort, P.I. & Tena-Sempere, M. 469 
(2010) Characterization of the inhibitory roles of RFRP3, the mammalian ortholog of GnIH, in 470 
the control of gonadotropin secretion in the rat: in vivo and in vitro studies. American 471 
Journal of Physiology - Endocrinology And Metabolism 299, E39-E46. 472 
Page 22 of 32Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 23
15 Kriegsfeld, L.J., Ubuka, T., Bentley, G.E. & Tsutsui, K. (2015) Seasonal control of 473 
gonadotropin-inhibitory hormone (GnIH) in birds and mammals. Frontiers in 474 
Neuroendocrinology 37, 65-75. 475 
16 Smith, J.T., Coolen, L.M., Kriegsfeld, L.J., Sari, I.P., Jaafarzadehshirazi, M.R., Maltby, 476 
M., Bateman, K., Goodman, R.L., Tilbrook, A.J., Ubuka, T., Bentley, G.E., Clarke, I.J. & 477 
Lehman, M.N. (2008) Variation in Kisspeptin and RFamide-Related Peptide (RFRP) Expression 478 
and Terminal Connections to Gonadotropin-Releasing Hormone Neurons in the Brain: A 479 
Novel Medium for Seasonal Breeding in the Sheep. Endocrinology 149, 5770-5782. 480 
17 Smith, J.T., Shahab, M., Pereira, A., Pau, K.-Y.F. & Clarke, I.J. (2010) Hypothalamic 481 
Expression of KISS1 and Gonadotropin Inhibitory Hormone Genes During the Menstrual 482 
Cycle of a Non-Human Primate. Biology of Reproduction 83, 568-577. 483 
18 George, J.T., Veldhuis, J.D., Roseweir, A.K., Newton, C.L., Faccenda, E., Millar, R.P. & 484 
Anderson, R.A. (2011) Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse 485 
Frequency in Men. Journal of Clinical Endocrinology & Metabolism 96, E1228-E1236. 486 
19 Flanagan, C.A., Fromme, B.J., Davidson, J.S. & Millar, R.P. (1998) A High Affinity 487 
Gonadotropin-Releasing Hormone (GnRH) Tracer, Radioiodinated at Position 6, Facilitates 488 
Analysis of Mutant GnRH Receptors. Endocrinology 139, 4115-4119. 489 
20 Lee, V.W.K., Cumming, I.A., de Kretser, D.M., Findlay, J.K., Hudson, B. & Keogh, E.J. 490 
(1976) Regulation of gonadotrophin secretion in rams from birth to sexual maturity. Journal 491 
of Reproduction and Fertility 46, 1-6. 492 
21 CLARKE, I.J. & CUMMINS, J.T. (1985) Increased Gonadotropin-Releasing Hormone 493 
Pulse Frequency Associated with Estrogen-Induced Luteinizing Hormone Surges in 494 
Ovariectomized Ewes. Endocrinology 116, 2376-2383. 495 
22 Clarke, I.J. (1993) Variable patterns of gonadotropin-releasing hormone secretion 496 
during the estrogen-induced luteinizing hormone surge in ovariectomized ewes. 497 
Endocrinology 133, 1624-1632. 498 
23 Salamonsen, L.A., Burger, H.G., Chamley, W.A. & Goding, J.R. (1972) 499 
Radioimmunoassay for ovine FSH. J Reprod Fertil 28, 131-132. 500 
24 Yoshida, H., Habata, Y., Hosoya, M., Kawamata, Y., Kitada, C. & Hinuma, S. (2003) 501 
Molecular properties of endogenous RFamide-related peptide-3 and its interaction with 502 
receptors. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1593, 151-157. 503 
25 George, J.T., Veldhuis, J.D., Tena-Sempere, M., Millar, R.P. & Anderson, R.A. (2013) 504 
Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: Kisspeptin-10 505 
stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild 506 
biochemical hypogonadism. Clinical Endocrinology 79, 100-104. 507 
26 George, J.T., Anderson, R.A. & Millar, R.P. (2012) Kisspeptin-10 stimulation of 508 
gonadotrophin secretion in women is modulated by sex steroid feedback. Human 509 
Reproduction 27, 3552-3559. 510 
27 Liu, P.Y., Keenan, D.M., Kok, P., Padmanabhan, V., O'Byrne, K.T. & Veldhuis, J.D. 511 
(2009) Sensitivity and specificity of pulse detection using a new deconvolution method. Am J 512 
Physiol Endocrinol Metab 297, E538-544. 513 
28 Anderson, G.M., Relf, H.-L., Rizwan, M.Z. & Evans, J.J. (2009) Central and Peripheral 514 
Effects of RFamide-Related Peptide-3 on Luteinizing Hormone and Prolactin Secretion in 515 
Rats. Endocrinology 150, 1834-1840. 516 
29 Tsutsui, K., Ubuka, T., Bentley, G.E. & Kriegsfeld, L. (2013) Review: Regulatory 517 
mechanisms of gonadotropin-inhibitory hormone (GnIH) synthesis and release in 518 
photoperiodic animals. Frontiers in Neuroscience 7. 519 
30 MacLean, D.B., Matsui, H., Suri, A., Neuwirth, R. & Colombel, M. (2014) Sustained 520 
Exposure to the Investigational Kisspeptin Analog, TAK-448, Down-Regulates Testosterone 521 
into the Castration Range in Healthy Males and in Patients With Prostate Cancer: Results 522 
Page 23 of 32 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 24
From Two Phase 1 Studies. The Journal of Clinical Endocrinology & Metabolism 99, E1445-523 
E1453. 524 
31 Son, Y.L., Ubuka, T., Millar, R.P., Kanasaki, H. & Tsutsui, K. (2012) Gonadotropin-525 
Inhibitory Hormone Inhibits GnRH-Induced Gonadotropin Subunit Gene Transcriptions by 526 
Inhibiting AC/cAMP/PKA-Dependent ERK Pathway in LŒ≤T2 Cells. Endocrinology 153, 2332-527 
2343. 528 
32 George, J.T., Kakkar, R., Marshall, J., Scott, M.L., Finkelman, R.D., Ho, T.W., Veldhuis, 529 
J., Skorupskaite, K., Anderson, R.A., McIntosh, S. & Webber, L. (2016) Neurokinin B Receptor 530 
Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled 531 
Trial. The Journal of Clinical Endocrinology & Metabolism 101, 4313-4321. 532 
 533 
  534 
Page 24 of 32Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 25
Supplementary data 535 
  536 
Page 25 of 32 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 26
 
Mean LH  
(IU) 
Number of  
Pulses 
Pulse Amplitude 
(IU) 
IPI  
(Min)  
Sheep 1 Prior to infusion 1.85 3 1.34 36.7 
 During infusion 2.6 4 1.94 43.3 
 After infusion 2.74 3 2.07 50 
      
Sheep 2 Prior to infusion 3.67 3 3.36 36.7 
 During infusion 3.68 4 4.59 42.5 
 After infusion 3.93 4 3.31 42.5 
   
Sheep 3 Prior to infusion 1.17 4 0.74 35 
 During infusion 1.38 4 0.53 37.5 
 After infusion 1.39 5 0.43 32 
   
Sheep 4 Prior to infusion 2.66 3 2.1 40 
 During infusion 2.83 4 2.9 42.5 
 After infusion 2.98 3 4.72 43.3 
   
Sheep 5 Prior to infusion 2.71 4 2.12 35 
 During infusion 2.36 4 0.89 40 
 After infusion 3.33 3 6.74 43.3 
   
Sheep 6 Prior to infusion 2.79 4 1.53 35 
 During infusion 3.31 4 1.89 40 
 After infusion 3.38 4 2.31 40 
      
Sheep 7 Prior to infusion 1.74 5 1.61 30 
 During infusion 1.97 4 1.96 35 
 After infusion 1.86 5 1.01 34 
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Sheep 8 Prior to infusion 3.5 3 2.94 46.7 
 During infusion 3.89 3 2.43 43.3 
 After infusion 3.95 4 2.21 42.5 
Supplementary table 1: LH secretory parameters (mean LH, pulse frequency, pulse 537 
amplitude and inter-pulse interval (IPI) in ovariectomised sheep administered GnIH (1mg/hr) 538 
or vehicle. Sheep 1, 4 , 7 and 8 were controls to sheep 2,3, 5 and 6 receiving GnIH. 539 
  540 
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 Mean LH (IU/L) 
Saline administration 
Mean LH (IU/L) 
GnIH administration 
Subject 1 Prior to infusion 21.8±0.9 20.4±0.5 
 During infusion 22.8±0.7 17.7±0.4 
 After infusion 24.5±0.7 20.1±0.4 
 
Subject 2 Prior to infusion 26.0±0.5 26.7±0.6 
 During infusion 28.3±0.5 26.7±0.9 
 After infusion 27.3±0.5 28.6±0.9 
 
   Subject 3 Prior to infusion 33.1±0.3 28.4±0.2 
 During infusion 33.3±0.3 27.8±0.3 
 After infusion 32.6±0.3 27.8±0.3 
 
Subject 4 Prior to infusion 40.3±0.9 42.4±1.0 
 During infusion 40.0±0.6 38.8±1.0 
 After infusion 39.2±0.6 36.7±1.0 
 
Subject 5 Prior to infusion 25.4±0.5 23.0±0.6 
 During infusion 23.4±0.4 21.6±0.5 
 After infusion N/A 19.0±0.5 
 541 
Supplementary table 2: Mean LH concentrations in five post menopausal women 542 
administered GnIH (50 mcg/kg) or saline infusions for 180 min. Data expressed as Mean 543 
±SEM of peripheral LH concentrations obtained at 10-min intervals for the 180 minutes 544 
preceding and 60 minutes following infusion. 545 
  546 
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 Saline administration visit GnIH administration visit 
 60-min 
AUC 
Baseline  
60-min 
AUC after 
first  
kisspeptin 
bolus 
60-min 
AUC after 
second 
kisspeptin 
bolus 
60-min 
AUC 
Baseline  
60-min 
AUC after 
first  
kisspeptin 
bolus 
60-min 
AUC after 
second 
kisspeptin 
bolus 
Subject 1 2.0 8.1 8.4 3.7 7.4 8.4 
Subject 2 5.1 6.8 6.9 3.4 6.5 6.4 
Subject 3 2.8 6.9 6.6 3.6 7.0 6.8 
Subject 4 1.3 4.1 4.2 1.8 3.8 3.7 
 547 
Supplementary table 3: Area-Under-Curve (IU/hr) in four male volunteers administered 548 
GnIH or saline infusions concurrently with kisspeptin-10 boluses. Increase in AUC after first 549 
kisspeptin-10 bolus indicates the stimulatory effect of kisspeptin-10 (0.3mcg/kg) on its own. 550 
The second bolus was administered concurrently with GnIH (50mcg/kg) or normal saline. 551 
AUCs following these second boluses of kisspeptin-10 were comparable to the first, 552 
suggesting a lack of modulatory effect of GnIH on kisspeptin-stimulated LH release. 553 
554 
Page 29 of 32 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 30
Supplementary Figures 555 
 556 
 557 
 558 
 559 
Supplementary Figure 1: In vitro comparsion of biological activity of the custom-560 
synthesised GMP grade human GnIH used in the present study with that of GnIH previously 561 
used in published data involving non-human species. Both peptides induced an inhibition of 562 
forskolin-induced accumulation of cAMP with similar potencies. RLU= relative luciferase 563 
units. N=3.  564 
  565 
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 567 
 568 
 569 
 570 
Supplementary Figure 2: LH pulse amplitude before (B), during (D) and after (A) vehicle or 571 
GnIH (1mg/hr) infusions in ovariectomised ewes (n=4) each. Significant reduction in the 572 
amplitude of LH pulses (ANOVA p<0.002) was observed during GnIH infusion.  573 
  574 
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